EUR 6.1
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 13.24 Million EUR | -244.64% |
2022 | 13.82 Million EUR | 105.45% |
2021 | 6.73 Million EUR | 606.93% |
2020 | 952 Thousand EUR | -25.39% |
2019 | 1.27 Million EUR | -56.63% |
2018 | 2.94 Million EUR | 23.72% |
2017 | 2.37 Million EUR | 8300.0% |
2016 | -29 Thousand EUR | -100.84% |
2015 | 3.46 Million EUR | -32.42% |
2014 | 5.12 Million EUR | 15.25% |
2013 | 4.44 Million EUR | -9.95% |
2012 | 4.93 Million EUR | 0.0% |
2011 | 4.93 Million EUR | 245.25% |
2010 | -3.39 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 Q4 | -24.26 Million EUR | 0.0% |
2023 Q2 | 3.96 Million EUR | 0.0% |
2022 Q2 | 4.84 Million EUR | 0.0% |
2022 FY | 13.82 Million EUR | 105.45% |
2022 Q4 | 5.4 Million EUR | 0.0% |
2021 Q2 | 847 Thousand EUR | 0.0% |
2021 FY | 6.73 Million EUR | 606.93% |
2021 Q4 | 5.88 Million EUR | 0.0% |
2020 Q2 | 1.06 Million EUR | 0.0% |
2020 Q4 | -2.66 Million EUR | 0.0% |
2020 FY | 952 Thousand EUR | -25.39% |
2019 FY | 1.27 Million EUR | -56.63% |
2019 Q2 | 8.45 Million EUR | 0.0% |
2019 Q4 | -7.17 Million EUR | 0.0% |
2018 Q4 | 2.97 Million EUR | 0.0% |
2018 FY | 2.94 Million EUR | 23.72% |
2018 Q2 | -1.59 Million EUR | 0.0% |
2017 Q4 | 4.22 Million EUR | 0.0% |
2017 Q2 | -1.84 Million EUR | 0.0% |
2017 FY | 2.37 Million EUR | 8300.0% |
2016 Q2 | -1.42 Million EUR | 0.0% |
2016 FY | -29 Thousand EUR | -100.84% |
2016 Q4 | 1.42 Million EUR | 0.0% |
2015 Q4 | 1.72 Million EUR | 0.0% |
2015 FY | 3.46 Million EUR | -32.42% |
2015 Q2 | 1.74 Million EUR | 0.0% |
2014 FY | 5.12 Million EUR | 15.25% |
2014 Q4 | 3.22 Million EUR | 0.0% |
2014 Q2 | 1.89 Million EUR | 0.0% |
2013 Q4 | 3.12 Million EUR | 0.0% |
2013 Q2 | 1.31 Million EUR | 0.0% |
2013 FY | 4.44 Million EUR | -9.95% |
2012 Q1 | 1.31 Million EUR | 0.0% |
2012 Q3 | 1.24 Million EUR | 0.0% |
2012 Q4 | 1.24 Million EUR | 0.0% |
2012 FY | 4.93 Million EUR | 0.0% |
2012 Q2 | 1.24 Million EUR | -4.94% |
2011 Q2 | 1.31 Million EUR | 254.4% |
2011 Q1 | -849.75 Thousand EUR | 0.0% |
2011 Q4 | 1.31 Million EUR | 0.0% |
2011 FY | 4.93 Million EUR | 245.25% |
2011 Q3 | 1.31 Million EUR | 0.0% |
2010 Q4 | -849.75 Thousand EUR | 0.0% |
2010 FY | -3.39 Million EUR | 0.0% |
2010 Q2 | -849.75 Thousand EUR | 0.0% |
2010 Q3 | -849.75 Thousand EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Crossject Société Anonyme | -11.8 Million EUR | 212.212% |
Safe Orthopaedics SA | -5.96 Million EUR | 322.09% |
Spineway SA | -9.03 Million EUR | 246.569% |
Sartorius Stedim Biotech S.A. | 484.5 Million EUR | 97.267% |
EssilorLuxottica Société anonyme | 3.17 Billion EUR | 99.583% |
bonyf N.V. | -39.89 Thousand EUR | 33290.38% |